5-FU AND CERVICAL CA

被引：0
|
作者：
TRELFORD, JD [1 ]
机构：
[1] UNIV CALIF,DEPT OBSTET & GYNECOL,DAVIS,CA
来源：
CA-A CANCER JOURNAL FOR CLINICIANS | 1974年 / 24卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：151 / 151
页数：1
相关论文
共 50 条
  • [41] Formulation and characterization of Paclitaxel, 5-FU and Paclitaxel+5-FU microspheres
    Gupte, A
    Ciftci, K
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 276 (1-2) : 93 - 106
  • [42] Uridine triacetate as an effective antidote in preclinical models of 5-FU overdoses and impaired 5-FU clearance.
    Von Borstel, Reid
    Garcia, Rolando
    Saydoff, Joel A.
    Bamat, Michael K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Trapping and degradation system of 5-FU active metabolite FdUMP by thymidylate synthase as a 5-FU resistance mechanism
    Nishizawa, Nana
    Sato, Akira
    CANCER SCIENCE, 2024, 115 : 669 - 669
  • [44] 5-FU induced encephalopathy during 5-FU containing regimen for esophageal squamous cell carcinoma.
    Kato, Ken
    Akiyoshi, Kohei
    Hokamura, Nobukazu
    Igaki, Hiroyasu
    Tachimori, Yuji
    Honma, Yoshitaka
    Iwasa, Satoru
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [45] SEQUENTIAL METHOTREXATE AND 5-FU IN CMFP (CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FU, AND PREDNISONE) THERAPY FOR BREAST-CANCER
    CADMAN, EC
    GLICK, JH
    CROSS, J
    HORTON, J
    TAYLOR, SG
    CANCER TREATMENT REPORTS, 1984, 68 (06): : 877 - 879
  • [46] To 5-FU or not to 5-FU? When, how and why to use the new active agents in advanced colorectal cancer
    Cvitkovic, E
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1296 - 1296
  • [47] A COMPARATIVE-STUDY OF PALA, PALA PLUS 5-FU, AND 5-FU IN ADVANCED BREAST-CANCER
    MANN, GB
    HORTOBAGYI, GN
    BUZDAR, AU
    YAP, HY
    VALDIVIESO, M
    CANCER, 1985, 56 (06) : 1320 - 1324
  • [48] 5-FU schedules, serum 5-FU levels and their relationship to therapy response and toxicity in patients with gastrointestinal cancer
    Blaschke, Martina
    Cameron, Silke
    Goeschen, Colin
    Ramadori, Giuliano
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (01) : 56 - 58
  • [49] Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil (5-FU) or 5-FU/oxaliplatin (5FU/OX) for rectal cancer
    Dolinsky, CM
    Mahmoud, NN
    Mick, R
    Sun, W
    Whittington, RW
    Solin, LJ
    Haller, DG
    Fry, RD
    Metz, JM
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S277 - S277
  • [50] 5-fluorouracil (5-FU) plasma exposure and outcome in patients receiving a TPF (taxotere, cisplatin, 5-FU) chemotherapy
    Legand, C.
    Blasco, H.
    Benz, I.
    Chapet, C.
    Le Guellec, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 25 - 25
12345